SEC Info - Nymox Pharmaceutical Corp.

SEC Info℠

Home

Help

Please Sign In

Nymox Pharmaceutical Corp. – ‘6-K’ for 3/28/24

On: Thursday, 3/28/24, at 1:03pm ET · For: 3/28/24 · Accession #: 1640334-24-510 · File #: 1-12033

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/28/24  Nymox Pharmaceutical Corp.        6-K         3/28/24    2:712K                                   Pubco Reporting … Inc/FA

Current, Quarterly or Annual Report by a Foreign Issuer — Form 6-K — SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Current, Quarterly or Annual Report by a Foreign    HTML     11K 
                Issuer                                                           
 2: EX-99.1     Press Release                                       HTML      4K

‘6-K’ — Current, Quarterly or Annual Report by a Foreign Issuer

This is an HTML Document rendered as filed. [ Alternative Formats ]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of March, 2024

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

(Translation of registrant’s name into English)

Bay & Deveaux Streets, Nassau, The Bahamas

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On March 27, 2024, Nymox Pharmaceutical Corporation (the “Company”) issued a press release announcing that the Company successfully obtained a formal order from the Bahamas Supreme Court resolving the Bahamas litigation brought by the Company’s terminated ex-employees. This press release is furnished as Exhibit 99.1 to this report on Form 6-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

EXHIBIT INDEX

Exhibit No.		Description

99.1		Press Release of Nymox Pharmaceutical Corporation, dated March 27, 2024

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 28, 2024

	NYMOX PHARMACEUTICAL CORPORATION

	By:	/s/ *Paul Averback*
	Name:	Paul Averback
	Title:	President and Chief Executive Officer

Dates Referenced Herein

This ‘6-K’ Filing	Date	Other Filings

Filed on / For Period end:	3/28/24	None on these Dates
	3/27/24
		List all Filings

↑Top

Filing Submission 0001640334-24-000510 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)